These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35306635)

  • 21. 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Bonfill Cosp X; Flicker L
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012216. PubMed ID: 29164603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer's Disease Biomarker and Mild Cognitive Impairment Diagnoses.
    Nation DA; Ho JK; Dutt S; Han SD; Lai MHC;
    J Alzheimers Dis; 2019; 69(4):1171-1182. PubMed ID: 31104015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarker-Based Risk Prediction of Alzheimer's Disease Dementia in Mild Cognitive Impairment: Psychosocial, Ethical, and Legal Aspects.
    Rostamzadeh A; Schwegler C; Gil-Navarro S; Rosende-Roca M; Romotzky V; Ortega G; Canabate P; Moreno M; Schmitz-Luhn B; Boada M; Jessen F; Woopen C
    J Alzheimers Dis; 2021; 80(2):601-617. PubMed ID: 33554900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evaluation of thiol-disulfıte balance, ischemıa albumın modıfıcation and seruloplazmine as a new oxidatıve stress in mild cognitive impairment and early stage alzheimer's disease patients.
    Gündüztepe Y; Bukan N; Zorlu E; Karaman Y; Andaç Topkan T; Gurbuz N; Neşelioğlu S; Erel Ö
    J Clin Neurosci; 2020 May; 75():188-194. PubMed ID: 32223973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
    Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L
    Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
    Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
    J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brief Cognitive Tests in the Case of Dementia and Alzheimer's Disease Early Diagnosis.
    Sagiadinou M; Plerou A
    Adv Exp Med Biol; 2020; 1195():127-135. PubMed ID: 32468467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Green RC; Harvey D; Jack CR; Jagust W; Luthman J; Morris JC; Petersen RC; Saykin AJ; Shaw L; Shen L; Schwarz A; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2015 Jun; 11(6):e1-120. PubMed ID: 26073027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Biomarker Combining Imaging and Neuropsychological Assessment for Tracking Early Alzheimer's Disease in Clinical Trials.
    Verma N; Beretvas SN; Pascual B; Masdeu JC; Markey MK;
    Curr Alzheimer Res; 2018 Mar; 15(5):429-442. PubMed ID: 29110613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Smailagic N; Vacante M; Hyde C; Martin S; Ukoumunne O; Sachpekidis C
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010632. PubMed ID: 25629415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients.
    Boccardi M; Nicolosi V; Festari C; Bianchetti A; Cappa S; Chiasserini D; Falini A; Guerra UP; Nobili F; Padovani A; Sancesario G; Morbelli S; Parnetti L; Tiraboschi P; Muscio C; Perani D; Pizzini FB; Beltramello A; Salvini Porro G; Ciaccio M; Schillaci O; Trabucchi M; Tagliavini F; Frisoni GB
    Eur J Neurol; 2020 Mar; 27(3):475-483. PubMed ID: 31692118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.
    Foster JK; Albrecht MA; Savage G; Lautenschlager NT; Ellis KA; Maruff P; Szoeke C; Taddei K; Martins R; Masters CL; Ames D;
    Brain; 2013 Jul; 136(Pt 7):2201-16. PubMed ID: 23737466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Biomarkers of the Alzheimer's disease: concepts and clinical case].
    Bier JC
    Rev Med Brux; 2013 Sep; 34(4):306-10. PubMed ID: 24195245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
    Mattsson N; Lönneborg A; Boccardi M; Blennow K; Hansson O;
    Neurobiol Aging; 2017 Apr; 52():196-213. PubMed ID: 28317649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.
    Dubois B; Villain N; Frisoni GB; Rabinovici GD; Sabbagh M; Cappa S; Bejanin A; Bombois S; Epelbaum S; Teichmann M; Habert MO; Nordberg A; Blennow K; Galasko D; Stern Y; Rowe CC; Salloway S; Schneider LS; Cummings JL; Feldman HH
    Lancet Neurol; 2021 Jun; 20(6):484-496. PubMed ID: 33933186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia.
    Ewers M; Sperling RA; Klunk WE; Weiner MW; Hampel H
    Trends Neurosci; 2011 Aug; 34(8):430-42. PubMed ID: 21696834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New clinical criteria for the Alzheimer's disease spectrum.
    Petersen RC
    Minn Med; 2012 Jan; 95(1):42-5. PubMed ID: 22355912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.